Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BMRA vs OSUR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OSUR Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 9–1 Matrix Metrics)

OSUR Overall Winner 6-Pillar Tally: BMRA 1 – 3 OSUR (2 Tie) Matrix Metrics: BMRA 1 – 9 OSUR

As of Nov 16, 2026, OraSure Technologies Inc (OSUR) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BMRA carries a Unified Composite Score of 44.5/100 (HOLD) at $1.36 (N/M Forward P/E, -125.2% operating margin), whereas OSUR carries 56.9/100 (HOLD) at $3.55 (40.0x Forward P/E, -58.2% operating margin).

  • Technical & Structure Timing Caution: BMRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0); meanwhile OSUR trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BMRA vs OSUR
BMRA NASDAQ
Biomerica Inc
In Vitro & In Vivo Diagnostic Substances
$1.36
+0.0% 1D
Market Cap $6.0M
TTM Revenue $4.3M
Forward P/E N/M
Beta / 30D Vol 0.67β · 62% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.7%), weak momentum, RSI 28
RSI-14: 28.0 · SMA20: $1.62 · SMA50: $1.96
OSUR NASDAQ Head-to-Head Winner
OraSure Technologies Inc
Surgical & Medical Instruments & Apparatus
$3.55
-1.96% 1D
Market Cap $250.0M
TTM Revenue $116M
Forward P/E 40.0x
Beta / 30D Vol 1.26β · 78% Vol
Unified Composite Score
56.9 / 100 HOLD
Tech 68.0 Fund 58.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 45.6 · SMA20: $3.74 · SMA50: $3.72

6-Pillar Scorecard Institutional Category Breakdown (BMRA 1 – 3 OSUR)

Columns: Metric · BMRA · OSUR
1. Valuation Multiples OSUR
Forward P/E N/M 40.0x
Trailing P/E N/M 40.0x
PEG Ratio N/M 6.19x
EV / Revenue 1.1x 2.2x
2. Growth & Scale OSUR
Revenue Growth (YoY) -8.3% +14.1%
Earnings Growth (YoY) +0.0% +29.6%
TTM Revenue (USD) $4.3M $116M
Market Cap $6.0M $250.0M
3. Profitability & Quality OSUR
Gross Margin 0.9% 43.1%
Operating Margin -125.2% -58.2%
Net Profit Margin -115.5% -41.7%
Return on Equity (ROE) -113.8% -14.5%
4. Balance Sheet & Cash Flow BMRA
Cash Generation (TTM) -$3.2M -$58M EBITDA
Cash Flow Margin -73.5% -50.2% EBITDA Mgn
Net Cash / Leverage $1.1M Net Cash $4.45 Book/Sh · -14.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 47.6% (77th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BMRA (1) vs OSUR (9)
Institutional Metric BMRA OSUR Criterion Row Edge
Market Capitalization
Scale
$6.0M $250.0M Larger Scale OSUR
Trailing P/E Ratio
Valuation
N/M 40.0x Lower Multiple OSUR
Forward P/E Ratio
Valuation
N/M 40.0x Lower Multiple OSUR
Revenue Growth (YoY)
Growth
-8.3% +14.1% Higher Growth OSUR
Operating Margin (TTM)
Profitability
-125.2% -58.2% Higher Margin OSUR
Net Profit Margin
Profitability
-115.5% -41.7% Higher Margin OSUR
Return on Equity (ROE)
Capital Efficiency
-113.8% -14.5% Higher ROE OSUR
52-Week Range Position
Momentum
5% ($1–$3) 59% ($2–$5) Stronger Trend OSUR
Beta / 30D Volatility
Risk Regime
0.67β · 62% Vol 1.26β · 78% Vol Lower Realized Risk BMRA
Unified Institutional Score
Composite Signal
44.5 / 100 (HOLD) 56.9 / 100 (HOLD) Higher Composite OSUR
Trailing 12M Revenue (USD)
Operating Scale
$4.3M $116M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
0.9% 43.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.1x EV/Rev 6.19x PEG · 2.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$3.2M ($1.1M Net Cash) -$58M EBITDA ($4.45 Book/Sh · -14.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OSUR +24.8 pp
BMRA: -26.49% · OSUR: -1.69%
3M Horizon OSUR +9.64 pp
BMRA: -15.0% · OSUR: -5.36%
6M Horizon OSUR +57.46 pp
BMRA: -39.56% · OSUR: +17.9%
1Y Horizon OSUR +101.25 pp
BMRA: -45.6% · OSUR: +55.65%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BMRA vs OSUR. Trailing 12-month operating profitability (BMRA -125.2% vs OSUR -58.2%) and valuation multiples (BMRA N/M vs OSUR 40.0x Forward P/E) are benchmarked directly in Pillar 4 below.

BMRA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.3M
Gross Margin0.9%
Op. Margin-125.2%
ROE / Fwd P/E-113.8% · N/M
OSUR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$116M
Gross Margin43.1%
Op. Margin-58.2%
ROE / Fwd P/E-14.5% · 40.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BMRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BMRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
OSUR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 47.6%
IV Percentile 77th %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact OSUR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BMRA Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $6.0M market capitalization and -125.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
OSUR Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $250.0M market capitalization and -58.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BMRA vs OSUR Key Questions & Quantitative Answers

As of Nov 16, 2026, OraSure Technologies Inc (OSUR) is the stronger overall head-to-head candidate over Biomerica Inc (BMRA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BMRA carries a Unified Composite Score of 44.5/100 (HOLD) at $1.36 (N/M Forward P/E, -125.2% operating margin), whereas OSUR carries 56.9/100 (HOLD) at $3.55 (40.0x Forward P/E, -58.2% operating margin). Technical & Structure Timing Caution: BMRA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0); meanwhile OSUR trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

OSUR leads the Growth & Scale pillar: BMRA posts -8.3% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (0.9% gross margin, -125.2% operating margin), compared with OSUR at +14.1% YoY revenue growth and +29.6% YoY earnings growth on $116M TTM revenue (43.1% gross margin, -58.2% operating margin). On trailing 12-month operating scale, BMRA generates $4.3M in USD-normalized revenue versus $116M for OSUR. In operating R&D and SG&A reinvestment, BMRA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OSUR.

OSUR screens cheaper on headline valuation multiples. BMRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-73.5% FCF margin), whereas OSUR trades at 40.0x Forward P/E, 40.0x Trailing P/E, 6.19x PEG, and 2.2x EV/Revenue (-50.2% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BMRA (-113.8% ROE) versus OSUR (-14.5% ROE) capital efficiency.

In options market volatility and institutional positioning, BMRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 62% Vol realized risk). By comparison, OSUR carries 47.6% implied volatility (77th %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.26β · 78% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.